Skip to main content
Equibles
TLPH logo

TLPH · Talphera, Inc. · Webcasts, Transcripts & Audio

Track TLPH — free

Use TLPH with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TLPH.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.16 +0.03 (+2.65%) At close · Oct 5
Rebalance outlook locked
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company has incurred recurring operating losses and negative cash flows from operating activities since inception and expects to continue to incur operating losses and negative cash flows in the future. These conditions raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 12, 2026
Market Cap
$61.25M
Shares
51.91M
Volume · Oct 5 587.12K Avg daily vol (3M) 280.53K

Talphera, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Talphera, Inc. (TLPH), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼100% $ −$6.75M '22 Q3 22-11-14 ▼22200% $ −$7.48M '22 Q4 23-03-30 · $253,000 −$4.37M '23 Q2 23-08-10 · $117,000 −$1.36M '23 Q3 23-11-08 · $ −$3.95M '24 Q1 24-05-14 ▼100% $ −$3.83M '24 Q2 24-08-14 ▼100% $ −$3.35M '24 Q3 24-11-13 · $ −$1.87M '24 Q4 25-03-31 · $27,000 −$2.59M '25 Q1 25-05-14 · $ −$3.49M '25 Q2 25-08-14 · $1,000 −$4.44M '25 Q3 25-11-12 · $ −$3.77M '25 Q4 26-03-23 ▼100% $ −$2.56M '26 Q1 26-05-13 LATEST · $ −$4.31M '26 Q2 26-08-12
Earnings call
FY26 · Q2
2026-08-12
Talphera, Inc. (TLPH) Q2 2026 Earnings Call Transcript
Confident tone NefroCRRT trial enrollment progress Product profile: ease of use and titration Commercial launch planning
Revenue
$
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-13
Talphera, Inc. (TLPH) Q1 2026 Earnings Call Transcript
Confident tone Nafamostat Clinical Advantages vs. Heparin/Citrate NEPHRO Study Enrollment Progress Niyad PMA Approval Pathway
Revenue
$
▼ 100% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-23
Talphera, Inc. (TLPH) Q4 2025 Earnings Call
Revenue
$*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-12
Talphera, Inc. (TLPH) Q3 2025 Earnings Call Transcript
Positive tone Nephro study enrollment and site activation Financing and capital position Nefamostat product profile and commercial positioning
Revenue
$1,000
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-14
Talphera, Inc. (TLPH) Q2 2025 Earnings Call Transcript
Confident tone Niyad/nafamostat regulatory and clinical positioning Heparin and citrate shortages / market need Compassionate use IDE
Revenue
$
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-14
Talphera, Inc. (TLPH) Q1 2025 Earnings Call Transcript
Confident tone NEPHRO CRRT trial progress Compassionate use IDE Niyad commercial opportunity
Revenue
$27,000
Diluted EPS
$-0.10
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-31
Talphera, Inc. (TLPH) Q4 2024 Earnings Call
Revenue
$*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-13
Talphera, Inc. (TLPH) Q3 2024 Earnings Call Transcript
Positive tone NEPHRO CRRT registrational trial Trial execution shortfalls and remediation Regulatory pathway and FDA
Revenue
$
▼ 100% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
Talphera, Inc. (TLPH) Q2 2024 Earnings Call Transcript
Positive tone Leadership transition and new Chief Development Officer NEPHRO study progress and site expansion Financial runway and capital position
Revenue
$
▼ 100% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
Talphera, Inc. (TLPH) Q1 2024 Earnings Call Transcript
Positive tone Market opportunity and pricing for Niyad Niyad product profile vs. heparin and citrate NEPHRO CRRT study and enrollment
Revenue
$
Diluted EPS
$-0.16
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-01-22
Talphera, Inc. (TLPH) Q4 2023 Earnings Call Transcript
Positive tone Niyad registrational study Market opportunity for regional anticoagulant Corporate rebranding and governance
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Talphera, Inc. (TLPH) Q3 2023 Earnings Call Transcript
Revenue
$117,000
Diluted EPS
$-0.08
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-10
Talphera, Inc. (TLPH) Q2 2023 Earnings Call Transcript
Revenue
$253,000
Diluted EPS
$-0.40
▼ 104.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-10
Talphera, Inc. (TLPH) Q1 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-30
Talphera, Inc. (TLPH) Q4 2022 Earnings Call
Revenue
$*
▼ 22200% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-14
Talphera, Inc. (TLPH) Q3 2022 Earnings Call
Revenue
$
▼ 100% YoY
Diluted EPS
$-0.94
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Talphera, Inc. (TLPH) Q2 2022 Earnings Call
Revenue
$
▼ 100% YoY
Diluted EPS
$8.58
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-16
Talphera, Inc. (TLPH) Q1 2022 Earnings Call
Revenue
$442,000
▼ 13.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-10
Talphera, Inc. (TLPH) Q4 2021 Earnings Call
Revenue
$2,000*
▼ 99.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-15
Talphera, Inc. (TLPH) Q3 2021 Earnings Call
Revenue
$1.86M
▲ 36.1% YoY
Diluted EPS
$-1.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-16
Talphera, Inc. (TLPH) Q2 2021 Earnings Call
Revenue
$443,000
▼ 84.8% YoY
Diluted EPS
$-1.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-17
Talphera, Inc. (TLPH) Q1 2021 Earnings Call
Revenue
$511,000
▲ 32.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-15
Talphera, Inc. (TLPH) Q4 2020 Earnings Call
Revenue
$738,000*
▲ 55.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Talphera, Inc. (TLPH) Q3 2020 Earnings Call
Revenue
$1.37M
▲ 125% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-16
Talphera, Inc. (TLPH) Q4 2019 Earnings Call
Revenue
$475,000
▼ 22.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–25 of 25 webcasts
Key facts CIK 1427925 CUSIP 00444T209 13F (30d) 2 filings 2 filers Visit website Investor relations